Our Story
In 2019, we launched our firm by focusing on the entrepreneurial community at Caltech. There we have found core science breakthroughs, deep tech innovation and a highly supportive environment for a new generation of founders.
In our first four years, we have invested in over 30 companies, forming our initial portfolio of category creating companies that leverage proprietary IP, AI, machine learning and other advanced technologies to move to market faster and more efficiently than ever.
Our Investment Model
From sourcing to support, our model is tailored to the needs of high-potential science-driven companies.
Connect
Develop deal flow in high quality scientific communities underserved by venture capital
Invest
Deploy capital at early stage human and planetary health companies enabled by AI and ML
Support
Serve founders and teams with non-science value add including fundraising, marketing, hiring and strategy


Convergent science yields new kinds of companies
Advanced computing power is driving a revolution in higher precision, cross-discipline innovation that moves more efficiently from the lab to the field. We're committed investors for companies leading this change.
Our numbers
Our investment segments represent the core areas where we apply our expertise and strategic insights to deliver optimal value. By focusing on these carefully selected market segments, we identify unique opportunities aligned with our clients' objectives.
$90M
AUM
Three funds to date: Fund One ($25M), Fund Two ($35M) and in early 2024, we closed our first Opportunity Fund at $15M. We also offered additional SPVs for breakout companies.
30+
Portfolio companies
We've invested in more than 30 companies at pre-seed, seed, Series A and Series B rounds. Deep tech that leverages computer science is our core thesis.
100+
Co-investors
Our companies continually attract co-investors from venture and corporate capital. We also regularly provide co-investment opportunities as companies grow and offer new value.

Press Release
Freeflow Ventures Raises $90M In Funding For Early Stage Deep Tech Investments
June 2024
Human Health
Iambic Therapeutics
Iambic Therapeutics has created a disruptive platform for small-molecule drug discovery by harnessing leadership in physics-informed AI and tightly integrating AI-driven design and experimental execution.
Planetary Health
StrokeDx
StrokeDx is transforming stroke diagnosis with non-invasive, non-radiating portable imaging technology.
Planetary Health
Captura
Captura is a revolutionary system for capturing carbon dioxide from ocean water at scale.
Human Health
Hydrosat
Hydrosat uses satellite imagery to provide geospatial intelligence for food security, public safety, and the environment.
Founder Sessions
Founder Sessions is our content series that sheds light on the origin stories of our portfolio company founders and leaders. These talks aim to educate and inspire our community
Flion Energy: Powering the New Geothermal
March 14, 2025
Membrion: Solving for Wastewater Recovery
October 10, 2024
Wild Microbes: Scaling New Bioproducts
September 25, 2024
Mitico
May 10, 2024
ImYoo
February 16, 2024
Switch Therapeutics
August 1, 2023
StrokeDx
July 12, 2023
polySpectra
March 8, 2023
DNATWO
March 1, 2023
Nuanced Health
January 10, 2023
Freeflow Ventures
October 18, 2022
H2U
October 7, 2022
Iambic Therapeutics (fka Entos)
September 6, 2022
Hydrosat
September 2, 2022
Unlocking the Translational Potential of University Innovation
September 17, 2020
News & Insight
We regularly post content and news from our portfolio companies and the Freeflow team









































